Protein Technologies

Application of Fabsorbent™ F1P HF, a Synthetic Ligand Adsorbent for Capture and Purification of a Single-Domain Antibody Fragment Expressed in Escherichia coli (PDF)
BioProcess International 7(7) (July - August 2009)

vCJD: An Ongoing Threat to Public Health and its Management (PDF)
Dr. Robert Rohwer, Patient Safety Conference 2010, London, England

An Improved Performance Adsorbent for the Downstream Processing of Serum Albumin and Related Fusion Proteins (PDF)
Bastiaan Lobbezoo, Ben Galarza, Jim Morritt, Chloe Booth, Jennifer Walden and Dev Baines, BioProcess International, Raleigh, NC.

A Synthetic Ligand Affinity Adsorbent for Capture and Purification of Genetically Engineered Antibody Fragment Therapeutics (PDF)
Sharon Williams, Bastiaan Lobbezoo, Michelle Stobbart, Helen Kirkman and Steve Burton, BioProcess International, Raleigh, NC

Characterization of a resin-nonwoven separation medium for removal of prions from complex suspension (PDF)
M.O.Hergistad, P.V.Gurgel, R.G.Carbonell, Prion2009 Conference Chalcidice, Greece

Biochemical quality of the pharmaceutically licensed plasma OctaplasLG(R) after implementation of a novel prion protein (PrPSC) removal technology and reduction of the solvent/detergent (S/D) process time (PDF)
A.Heger, T.-E.Svae, A.Neisser-Svae, S.Jordan, M.Behizad & J.Romisch

Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG(R) (PDF)
A.Neisser-Svae, A.Bailey, L.Gregori, A.Heger, S.Jordan, M.Behizad, H.Reichl, J.Romisch & T.-E.Svae,

In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma™ P-CAPT prion-reduction filter (PDF)
C.V. Murphy, E. Eakins, J. Fagan, H. Croxon & W.G. Murphy, Transfusion Medicine, 2009, 19, 109-116

Prion Infectivity Removal from Human Plasma and Plasma Products Using Affinity Ligands (PDF)
L. Gregori, B. Lambert,P.V. Gurgel, J. Lathrop,M. Behizad, S. Jordan, and R. Rohwer, Plasma Product Biotechnology Meeting 2009Menorca, Spain

The potential for low cost manufacturing of safe plasma products (PDF – Read-only), PPB09 Menorca, Spain - John Curling, Christopher Bryant, Tom Chen, Timothy Hayes, ProMetic BioTherapeutics, Inc., Neil Goss, Further Options Ltd.,Andrew Sinclair, Janice Lim, BioPharm Services Ltd., Mahesh Prashad, Sartorius Stedim Biotech

Alternatives to Protein A capture (PDF) Dev Baines, Sharon Williams, Steve Burton, EuroBiotechNews Nº 3-4, Volume 8, 2009

Determination of Specificity and Capacity for the P-Capt(TM) Prion Removal Filter (PDF) L. Gregori, J.T. Lathrop, P.V. Gurgel, N. Lescoutra, R.G. Rohwer ISBT 2009

Hybrid Particle-Nonwoven Membrane separation Medium for Removal of Pathogenic Contaminants from Red Blood Cell Concentrate (PDF) M.O. Herigstad, P.V. Gurgel, R.G. Carbonnell

Depletion of high abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column (PDF) Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC, Strancar A. J Chromatogr A. 2009; 1216:2689-2694

Development of a Device for Reduction of Prion Infectivity from Red Blood Cell Concentrate (PDF)
P.V. Gurgel, L. Gregori, J. Lathrop, R.G. Carbonell, R. Rohwer, S. Burton
PrPCanada 2009

Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study (PDF)
Simon Mead, Mark Poulter, James Uphill, John Beck, Jerome Whitfield, Thomas EF Webb, Tracy Campbell, Gary Adamson, Pelagia Deriziotis, Sarah J Tabrizi, Holger Hummerich, Claudio Verzilli, Michael P Alpers, John C Whittaker, John Collinge
Lancet Neural 2009;8:57-66

Specificity and capacity of the P-Capt(R) filter for prion protein and prion infectivity (PDF)
Prion 2008

Reduction of prion from red cells, plasma and plasma products using specific affinity ligands (PDF)
Prion 2008

Removal of prion infectivity from plasma-derived products (PDF)
Recovery of Biological Products 13 Conference

Prion Safety and Transfusion Plasma Abstract Book (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

The introduction of a novel prion protein (PrPSc) removal technology for the pharmaceutically licensed plasma Octaplas® (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

Biochemical quality of the pharmaceutically licensed plasma Octaplas® after implementation of a novel prion protein (PrPSc) removal technology (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

Development of a device for prion reduction based on affinity ligand (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. Patrick Gurgel

Managing the risks from blood associated TSE infectivity with prion affinity ligands (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. R. Rohwer

Process Chromatography – Five Decades of Innovation (PDF)
Curling J.M.
Biopharm International, February 2007

Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands (PDF)
Luisa Gregori, Brian C. Lambert, Patrick V. Gurgel, Liliana Gheorghiu, Peter Edwardson, Julia T. Lathrop, Claudia MacAuley, Ruben G. Carbonell, Steven J. Burton, David Hammond, and Robert G. Rohwer
Transfusion, Volume 46, pp. 1152-1161, July 2006

Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins (PDF)
Luisa Gregori, Patrick V Gurgel, Julia T Lathrop, Peter Edwardson, Brian C Lambert, Ruben G Carbonell, Steven J Burton, David J Hammond, Robert
G Rohwer
Lancet 2006; 368: 2232–36

Prion reduction filters (PDF)
Marc L Turner, Edinburgh Blood Transfusion Centre, Royal Infi rmary of Edinburgh
Lancet 2006; Vol 368 December 23/30

The Plasma Fractionation Industry. New Opportunities To Move Forward? (PDF)
Curling, J.M. and Bryant, C.
BioProcess International, March 2005

New Challenges for Biopharmaceutical Process Development (PDF)
Curling, J.M.
Biotechnology Focus, February 2005

Affinity chromatography – from textile dyes to synthetic ligands by design. Part 2
Curling, J. M.
BioPharm Intl. 17, No. 8, 60-66, August 2004.

Affinity chromatography – from textile dyes to synthetic ligands by design. Part 1
Curling, J. M.
BioPharm Intl. 17, No. 7, 34-42, July 2004.

Integrating new technology into blood plasma fractionation
Curling, J. M.
BioPharm 15, No. 9, 16-25, September 2002.

Affinity Chromatography
Smiley, L., and Curling, J.M.
Genetic Engineering News, November 15, 2001.

Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins
Behizad, B., Curling, J.M.
Biopharm, Vol 13 No 7 pp. 42–46., September 2000.

Development and Commercialization of Biomimetics
Burton, J.
Link, Collaborative Research, 2000.

Regulatory Aspects of Column chromatography in Biopharmaceutical Manufacturing
Behizad, M., Baines, D.
Biopharm Vol 11 No 5, May 1998.

Design, Synthesis, and Application of a Protein A Mimetic
Li, Rongxiu., Dowd, V., Stewart, D.J., Burton, S.J., Lowe, C.R.
Nature Biotechnology, Vol 16, pp. 190–195, February 1998.

Protein Technologies

Scientific Library

Therapeutics

PBI-1402

Autoimmune Diseases

Miscellaneous

Protein Technologies